Zhitong Finance App News, Shanghai Pharmaceutical (02607.HK) issued an announcement. Recently, Shanghai Shangyao First Biochemical Co., Ltd. (hereinafter referred to as “Shanghai Pharmaceutical First Biochemical”), a subsidiary of Shanghai Pharmaceutical Group Co., Ltd. (hereinafter referred to as the “Company”), received the “Drug Registration Certificate” (certificate numbers: 2026S03524, 2026S03525) issued by the China Drug Administration (hereinafter referred to as the “State Drug Administration”) for clovidipine emulsion injections (hereinafter referred to as “this drug”).
Zhitongcaijing · 1d ago
Share
Listen to the news
Zhitong Finance App News, Shanghai Pharmaceutical (02607.HK) issued an announcement. Recently, Shanghai Shangyao First Biochemical Co., Ltd. (hereinafter referred to as “Shanghai Pharmaceutical First Biochemical”), a subsidiary of Shanghai Pharmaceutical Group Co., Ltd. (hereinafter referred to as the “Company”), received the “Drug Registration Certificate” (certificate numbers: 2026S03524, 2026S03525) issued by the China Drug Administration (hereinafter referred to as the “State Drug Administration”) for clovidipine emulsion injections (hereinafter referred to as “this drug”).
Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending